257 related articles for article (PubMed ID: 30288884)
1. Evaluation of axitinib to downstage cT2a renal tumours and allow partial nephrectomy: a phase II study.
Lebacle C; Bensalah K; Bernhard JC; Albiges L; Laguerre B; Gross-Goupil M; Baumert H; Lang H; Tricard T; Duclos B; Arnoux A; Piedvache C; Patard JJ; Escudier B
BJU Int; 2019 May; 123(5):804-810. PubMed ID: 30288884
[TBL] [Abstract][Full Text] [Related]
2. PADRES: a phase 2 clinical trial of neoadjuvant axitinib for complex partial nephrectomy.
Hakimi K; Campbell SC; Nguyen MV; Rathi N; Wang L; Meagher MF; Rini BI; Ornstein M; McKay RR; Derweesh IH
BJU Int; 2024 Apr; 133(4):425-431. PubMed ID: 37916303
[TBL] [Abstract][Full Text] [Related]
3. Variability of inter-observer agreement on feasibility of partial nephrectomy before and after neoadjuvant axitinib for locally advanced renal cell carcinoma (RCC): independent analysis from a phase II trial.
Karam JA; Devine CE; Fellman BM; Urbauer DL; Abel EJ; Allaf ME; Bex A; Lane BR; Thompson RH; Wood CG
BJU Int; 2016 Apr; 117(4):629-35. PubMed ID: 26033220
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.
Karam JA; Devine CE; Urbauer DL; Lozano M; Maity T; Ahrar K; Tamboli P; Tannir NM; Wood CG
Eur Urol; 2014 Nov; 66(5):874-80. PubMed ID: 24560330
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial.
Huang J; Wang Y; Xu F; Wang Z; Wu G; Kong W; Cheoklong NG; Tricard T; Wu X; Zhai W; Zhang W; Zhang J; Zhang D; Chen S; Lian Y; Chen Y; Zhang J; Huang Y; Xue W
J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38862251
[TBL] [Abstract][Full Text] [Related]
6. Partial nephrectomy for renal masses ≥ 7 cm: technical, oncological and functional outcomes.
Long CJ; Canter DJ; Kutikov A; Li T; Simhan J; Smaldone M; Teper E; Viterbo R; Boorjian SA; Chen DY; Greenberg RE; Uzzo RG
BJU Int; 2012 May; 109(10):1450-6. PubMed ID: 22221502
[TBL] [Abstract][Full Text] [Related]
7. Study of the Kidney Tumor-Parenchymal Interface after Neoadjuvant Treatment with Axitinib for Locally Advanced Clear Cell Renal Cell Carcinoma: Matched Analysis from a Phase II Trial.
Kawakami F; Rao P; Tamboli P; Wood CG; Karam JA
J Urol; 2017 Mar; 197(3 Pt 1):559-565. PubMed ID: 27678298
[TBL] [Abstract][Full Text] [Related]
8. Survival after partial and radical nephrectomy for the treatment of stage T1bN0M0 renal cell carcinoma (RCC) in the USA: a propensity scoring approach.
Badalato GM; Kates M; Wisnivesky JP; Choudhury AR; McKiernan JM
BJU Int; 2012 May; 109(10):1457-62. PubMed ID: 21933334
[TBL] [Abstract][Full Text] [Related]
9. Tumour size, tumour complexity, and surgical approach are associated with nephrectomy type in small renal cortical tumours treated electively.
Broughton GJ; Clark PE; Barocas DA; Cookson MS; Smith JA; Herrell SD; Chang SS
BJU Int; 2012 Jun; 109(11):1607-13. PubMed ID: 21939493
[TBL] [Abstract][Full Text] [Related]
10. A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma.
Rini BI; Plimack ER; Takagi T; Elson P; Wood LS; Dreicer R; Gilligan T; Garcia J; Zhang Z; Kaouk J; Krishnamurthi V; Stephenson AJ; Fergany A; Klein EA; Uzzo RG; Chen DY; Campbell SC
J Urol; 2015 Aug; 194(2):297-303. PubMed ID: 25813447
[TBL] [Abstract][Full Text] [Related]
11. Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies.
Mir MC; Derweesh I; Porpiglia F; Zargar H; Mottrie A; Autorino R
Eur Urol; 2017 Apr; 71(4):606-617. PubMed ID: 27614693
[TBL] [Abstract][Full Text] [Related]
12. Application of the Stage, Size, Grade, and Necrosis (SSIGN) Score for Clear Cell Renal Cell Carcinoma in Contemporary Patients.
Parker WP; Cheville JC; Frank I; Zaid HB; Lohse CM; Boorjian SA; Leibovich BC; Thompson RH
Eur Urol; 2017 Apr; 71(4):665-673. PubMed ID: 27287995
[TBL] [Abstract][Full Text] [Related]
13. Comparison of progression to end-stage renal disease requiring dialysis after partial or radical nephrectomy for renal cell carcinoma in patients with severe chronic kidney disease.
Takagi T; Kondo T; Omae K; Iizuka J; Kobayashi H; Yoshida K; Hashimoto Y; Tanabe K
Int Urol Nephrol; 2016 Sep; 48(9):1421-7. PubMed ID: 27193433
[TBL] [Abstract][Full Text] [Related]
14. Survival outcomes after radical and partial nephrectomy for clinical T2 renal tumours categorised by R.E.N.A.L. nephrometry score.
Kopp RP; Mehrazin R; Palazzi KL; Liss MA; Jabaji R; Mirheydar HS; Lee HJ; Patel N; Elkhoury F; Patterson AL; Derweesh IH
BJU Int; 2014 Nov; 114(5):708-18. PubMed ID: 24274650
[TBL] [Abstract][Full Text] [Related]
15. Partial nephrectomy is not associated with an overall survival advantage over radical nephrectomy in elderly patients with stage Ib-II renal masses: An analysis of the national cancer data base.
Ristau BT; Handorf EA; Cahn DB; Kutikov A; Uzzo RG; Smaldone MC
Cancer; 2018 Oct; 124(19):3839-3848. PubMed ID: 30207380
[TBL] [Abstract][Full Text] [Related]
16. Renal Functional Outcome of Partial Nephrectomy for Complex R.E.N.A.L. Score Tumors With or Without Neoadjuvant Sunitinib: A Multicenter Analysis.
McDonald ML; Lane BR; Jimenez J; Lee HJ; Yim K; Bindayi A; Hamilton ZA; Field CA; Bloch AS; Dey S; Noyes S; McKay R; Millard F; Rini BI; Campbell SC; Derweesh IH
Clin Genitourin Cancer; 2018 Apr; 16(2):e289-e295. PubMed ID: 29113767
[TBL] [Abstract][Full Text] [Related]
17. Overall survival and oncological outcomes after partial nephrectomy and radical nephrectomy for cT2a renal tumors: A collaborative international study from the French kidney cancer research network UroCCR.
Reix B; Bernhard JC; Patard JJ; Bigot P; Villers A; Suer E; Vuong NS; Verhoest G; Alimi Q; Beauval JB; Benoit T; Nouhaud FX; Lenormand C; Hamidi N; Cai J; Eto M; Larre S; El Bakhri A; Ploussard G; Hung A; Koutlidis N; Schneider A; Carrouget J; Droupy S; Marchal S; Doerfler A; Seddik S; Matsugasumi T; Orsoni X; Descazeaud A; Pfister C; Bensalah K; Soulie M; Gill I; Flamand V;
Prog Urol; 2018 Mar; 28(3):146-155. PubMed ID: 29331568
[TBL] [Abstract][Full Text] [Related]
18. Should patients with low-risk renal cell carcinoma be followed differently after nephron-sparing surgery vs radical nephrectomy?
Abu-Ghanem Y; Powles T; Capitanio U; Beisland C; Järvinen P; Stewart GD; Gudmundsson E; Lam TBL; Marconi L; Fernandéz-Pello S; Nisen H; Meijer RP; Volpe A; Ljungberg B; Klatte T; Bensalah K; Dabestani S; Bex A
BJU Int; 2021 Sep; 128(3):386-394. PubMed ID: 33794055
[TBL] [Abstract][Full Text] [Related]
19. Does the Unexpected Presence of Non-organ-confined Disease at Final Pathology Undermine Cancer Control in Patients with Clinical T1N0M0 Renal Cell Carcinoma Who Underwent Partial Nephrectomy?
Capitanio U; Stewart GD; Klatte T; Akdogan B; Roscigno M; Marszalek M; Dell'Oglio P; Zaffuto E; Rodriguez Faba O; Salagierski M; Lingard J; Carini M; Ouzaid I; Mir MC; Montorsi F; Da Pozzo LF; Stief C; Minervini A; Brookman-May SD
Eur Urol Focus; 2018 Dec; 4(6):972-977. PubMed ID: 28753867
[TBL] [Abstract][Full Text] [Related]
20. Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma.
Lane BR; Derweesh IH; Kim HL; O'Malley R; Klink J; Ercole CE; Palazzi KL; Thomas AA; Rini BI; Campbell SC
Urol Oncol; 2015 Mar; 33(3):112.e15-21. PubMed ID: 25532471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
